Hitoshi Kusaba

2.4k total citations
112 papers, 1.8k citations indexed

About

Hitoshi Kusaba is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Hitoshi Kusaba has authored 112 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Oncology, 35 papers in Pulmonary and Respiratory Medicine and 26 papers in Molecular Biology. Recurrent topics in Hitoshi Kusaba's work include Colorectal Cancer Treatments and Studies (23 papers), Cancer Treatment and Pharmacology (18 papers) and Gastric Cancer Management and Outcomes (16 papers). Hitoshi Kusaba is often cited by papers focused on Colorectal Cancer Treatments and Studies (23 papers), Cancer Treatment and Pharmacology (18 papers) and Gastric Cancer Management and Outcomes (16 papers). Hitoshi Kusaba collaborates with scholars based in Japan, United States and Canada. Hitoshi Kusaba's co-authors include Eishi Baba, Koichi Akashi, Hiroshi Ariyama, Michihiko Kuwano, Morimasa Wada, Taishi Harada, Masaaki Nakayama, Mamoru Ito, Kenji Tsuchihashi and Shuji Arita and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Hitoshi Kusaba

105 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hitoshi Kusaba Japan 24 946 772 387 307 249 112 1.8k
Taigo Kato Japan 27 633 0.7× 547 0.7× 307 0.8× 402 1.3× 326 1.3× 118 1.6k
Hiroshi Ariyama Japan 20 804 0.8× 426 0.6× 290 0.7× 280 0.9× 259 1.0× 84 1.4k
Antonella Argentiero Italy 23 794 0.8× 596 0.8× 326 0.8× 406 1.3× 140 0.6× 48 1.6k
Virote Sriuranpong Thailand 21 1.1k 1.1× 995 1.3× 381 1.0× 236 0.8× 205 0.8× 77 2.2k
Eijiro Nakamura Japan 19 574 0.6× 512 0.7× 472 1.2× 229 0.7× 233 0.9× 59 1.4k
Aristidis Polyzos Greece 24 1.3k 1.4× 718 0.9× 481 1.2× 507 1.7× 275 1.1× 67 2.4k
Carmela Pisano Italy 26 706 0.7× 532 0.7× 261 0.7× 212 0.7× 321 1.3× 95 1.9k
Olaf Christensen United States 16 847 0.9× 542 0.7× 321 0.8× 415 1.4× 117 0.5× 25 1.5k
Carsten Grüllich Germany 25 493 0.5× 557 0.7× 479 1.2× 264 0.9× 213 0.9× 90 1.5k
Rohan Garje United States 17 1.1k 1.2× 429 0.6× 556 1.4× 422 1.4× 187 0.8× 79 1.8k

Countries citing papers authored by Hitoshi Kusaba

Since Specialization
Citations

This map shows the geographic impact of Hitoshi Kusaba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hitoshi Kusaba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hitoshi Kusaba more than expected).

Fields of papers citing papers by Hitoshi Kusaba

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hitoshi Kusaba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hitoshi Kusaba. The network helps show where Hitoshi Kusaba may publish in the future.

Co-authorship network of co-authors of Hitoshi Kusaba

This figure shows the co-authorship network connecting the top 25 collaborators of Hitoshi Kusaba. A scholar is included among the top collaborators of Hitoshi Kusaba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hitoshi Kusaba. Hitoshi Kusaba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nio, Kenta, et al.. (2024). P91-4 A case of immune checkpoint inhibitor-associated myasthenia gravis in advanced breast cancer. Annals of Oncology. 35. S1394–S1394.
2.
Fukata, Mitsuhiro, Michinari Hieda, Taku Yokoyama, et al.. (2022). Early-onset cardiac dysfunction following allogeneic haematopoietic stem cell transplantation. Open Heart. 9(1). e002007–e002007. 5 indexed citations
3.
4.
Nishikawa, Kazuo, Shuichi Hironaka, Takashi Inagaki, et al.. (2022). A multicentre retrospective study comparing site-specific treatment with empiric treatment for unfavourable subset of cancer of unknown primary site. Japanese Journal of Clinical Oncology. 52(12). 1416–1422. 2 indexed citations
5.
Hieda, Michinari, Taku Yokoyama, Mitsuhiro Fukata, et al.. (2022). Effect of renin–angiotensin system inhibitors in patients with cancer treated with anti-VEGF therapy. Open Heart. 9(2). e002135–e002135. 3 indexed citations
6.
7.
Tsuchihashi, Kenji, Hirofumi Ohmura, Toshihiro Yamaguchi, et al.. (2020). RNA N6-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cells. Biochemical and Biophysical Research Communications. 530(1). 235–239. 69 indexed citations
8.
Kusaba, Hitoshi, Michitaka Nakano, Masato Komoda, et al.. (2019). Hypoalbuminemia for the prediction of venous thromboembolism and treatment of direct oral anticoagulants in metastatic gastric cancer patients. Gastric Cancer. 22(5). 988–998. 22 indexed citations
9.
10.
Nakano, Michitaka, et al.. (2017). Tumor infiltrating lymphocytes in malignant ascites predict prognosis of gastrointestinal cancer. 1242. 1 indexed citations
11.
Shirakawa, Tsuyoshi, Michitaka Nakano, Kenta Nio, et al.. (2016). Retrospective analysis of cardiovascular diseases related to chemotherapies for advanced solid tumor patients. Anti-Cancer Drugs. 27(9). 891–898. 2 indexed citations
12.
Shirakawa, Tsuyoshi, et al.. (2015). Improvement in the awareness of palliative care nursing using STAS-J in an acute care hospital. Annals of Oncology. 26. vii88–vii88.
13.
Tsuchihashi, Kenji, Keita Uchino, Tsuyoshi Shirakawa, et al.. (2012). Systemic chemotherapy for metastatic non-mucinous appendiceal adenocarcinoma: a case report and literature review. International Cancer Conference Journal. 2(1). 36–40.
14.
Baba, Eishi, Taito Esaki, Hiroshi Ariyama, et al.. (2010). Phase II study of sequential treatment with S-1 and cisplatin for metastatic gastric cancer. Cancer Chemotherapy and Pharmacology. 68(3). 611–617. 1 indexed citations
15.
Shibata, Yoshihiro, Eishi Baba, Hiroshi Ariyama, et al.. (2010). Irinotecan-based combination chemotherapy for metastatic small intestinal adenocarcinoma. Oncology Letters. 1(3). 423–426. 1 indexed citations
16.
Yamada, Yasuhide, Tomohide Tamura, Noboru Yamamoto, et al.. (2005). Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 58(2). 173–182. 15 indexed citations
17.
Tanaka, Risa, Yasushi Takii, Yoshihiro Shibata, et al.. (2005). In vitro sequence-dependent interaction between nedaplatin and paclitaxel in human cancer cell lines. Cancer Chemotherapy and Pharmacology. 56(3). 279–285. 9 indexed citations
18.
Yano, Shingo, Paritosh Ghosh, Hitoshi Kusaba, M Buchholz, & Dan L. Longo. (2003). Effect of Promoter Methylation on the Regulation of IFN- γ Gene During In Vitro Differentiation of Human Peripheral Blood T Cells into a Th2 Population. The Journal of Immunology. 171(5). 2510–2516. 98 indexed citations
19.
Harada, Taishi, Hitoshi Kusaba, Takeshi Uchiumi, et al.. (1998). Localization of 67 Exons on a YAC Contig Spanning 1.5 Mb around the Multidrug Resistance Gene Region of Human Chromosome 7q21.1. Genomics. 49(1). 14–22. 6 indexed citations
20.
Torigoe, K, Seiji Sato, Hitoshi Kusaba, et al.. (1995). A YAC-based contig of 1.5 Mb spanning the human multidrug resistance gene region and delineating the amplification unit in three human multidrug-resistant cell lines.. Genome Research. 5(3). 233–244. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Taigo Kato Breakdown of academic impact, for papers by Hiroshi Ariyama Breakdown of academic impact, for papers by Antonella Argentiero Breakdown of academic impact, for papers by Virote Sriuranpong Breakdown of academic impact, for papers by Eijiro Nakamura Breakdown of academic impact, for papers by Aristidis Polyzos Breakdown of academic impact, for papers by Carmela Pisano Breakdown of academic impact, for papers by Olaf Christensen Breakdown of academic impact, for papers by Carsten Grüllich Breakdown of academic impact, for papers by Rohan Garje
Rankless by CCL
2026